WuXi XDC Cayman (FRA:L74) EV-to-EBIT : 78.21 (As of May. 12, 2024)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, WuXi XDC Cayman's Enterprise Value is €2,190.1 Mil. WuXi XDC Cayman's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €28.0 Mil. Therefore, WuXi XDC Cayman's EV-to-EBIT for today is 78.21.

The historical rank and industry rank for WuXi XDC Cayman's EV-to-EBIT or its related term are showing as below:

FRA:L74' s EV-to-EBIT Range Over the Past 10 Years
Min: 49.82 Med: 71.63 Max: 116.99
Current: 77.63

During the past 4 years, the highest EV-to-EBIT of WuXi XDC Cayman was 116.99. The lowest was 49.82. And the median was 71.63.

FRA:L74's EV-to-EBIT is ranked worse than
90.57% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.34 vs FRA:L74: 77.63

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. WuXi XDC Cayman's Enterprise Value for the quarter that ended in Jun. 2023 was €0.0 Mil. WuXi XDC Cayman's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €28.0 Mil. WuXi XDC Cayman's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.

WuXi XDC Cayman EV-to-EBIT Historical Data

The historical data trend for WuXi XDC Cayman's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman EV-to-EBIT Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

79.87

WuXi XDC Cayman Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of WuXi XDC Cayman's EV-to-EBIT

For the Diagnostics & Research subindustry, WuXi XDC Cayman's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi XDC Cayman's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's EV-to-EBIT falls into.

WuXi XDC Cayman EV-to-EBIT Calculation

WuXi XDC Cayman's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2190.079	/	28.003
	=	78.21

WuXi XDC Cayman's current Enterprise Value is €2,190.1 Mil.
WuXi XDC Cayman's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.0 Mil.

WuXi XDC Cayman (FRA:L74) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

WuXi XDC Cayman's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	28.003	/	0
	=	%

WuXi XDC Cayman's Enterprise Value for the quarter that ended in Jun. 2023 was €0.0 Mil.
WuXi XDC Cayman's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.0 Mil.

WuXi XDC Cayman EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman (FRA:L74) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (FRA:L74) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

02268:Hong Kong

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (FRA:L74) Headlines

No Headlines